Answers are grounded in this paper and cite their sources.
// Yuting Zhan 1 , Hongjing Zang 1 , Juan Feng 1 , Junmi Lu 1 , Lingjiao Chen 1 and Songqing Fan 1 1 Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Correspondence to: Songqing Fan, email: songqingfan@csu.edu.cn Keywords: NSCLC, lncRNAs, chemotherapy, radiotherapy, molecular therapy Received: May 01, 2017 Accepted: July 26, 2017 Published: August 09, 2017 ABSTRACT Lung cancer, with 80–85% being non-small cell lung cancer (NSCLC), is the leading cause of cancer-related death in both men and women. Long non-coding RNAs (lncRNAs), always defined as non-protein-coding RNA molecules longer than 200 nucleotides, are now thought as a new frontier in the study of human malignant diseases including NSCLC. As researches continue, increasing number of roles that lncRNAs play in NSCLC has been found, and more and more evidences show lncRNAs have a close relationship with patients’ response to radiochemotherapy or molecular therapy. The aim of this review is to disclose the roles that lncRNAs play in NSCLC and how lncRANs influence the treatment of NSCLC.
No takes yet. Share an insight, caveat, or question.
Zhan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: